Search

Icotrokinra

Icotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist. … [L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108]

TAK-428

It is based on the novel concept that peripheral nervous tissue that was damaged by diabetes can be repaired and regenerated by stimulating an increase in neurotrophic factors.

Arzoxifene

Calcium glucoheptonate

Calcium supplements such as calcium gluceptate are taken by individuals who are unable to get enough calcium in their regular diet or who have a need for more calcium. … They are used to prevent or treat several conditions that may cause hypocalcemia (not enough calcium in the blood). The body needs calcium to make strong bones.

Trapidil

Trapidil, a platelet-derived growth factor antagonist, was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney disease.

Transcrocetinate

Vitamin A-analog that increases diffusivity of oxygen in aqueous solutions, including plasma.

Nafarelin

Nafarelin has been used in the treatments of central precocious puberty and endometriosis.

Human immunoglobulin G

IVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders. … IVIg contains the same distribution of IgG antibody subclasses as is found in the general human population.

Tildrakizumab

A study was performed on the pharmacokinetics of this drug on various ethnicities. The pharmacokinetics of tildrakizumab were similar in Japanese, Caucasian, and Chinese subjects [A32257]. … Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis [A32255].

Depreotide

Depreotide is an ingredient in the EMA-withdrawn product NeoSpect.